Psoriasis, as a chronic, recurrent, and inflammatory skin disease, not only imposes physical and psychological burdens on patients but also demands more rational allocation of medical resources. To advance the development of psoriasis treatment, improve precision diagnosis and therapy, ensure the rational and safe use of biologics, implement comprehensive chronic disease management, and alleviate the disease burden on patients, the Sichuan Province Psoriasis Single-Disease Quality Control Initiative Kickoff Meeting, organized by the Chengdu High-Tech Zone Medical Association, was successfully held in Yibin City on February 15, 2025.

       This meeting established unified quality control standards and clinical pathways, which will effectively enhance the diagnosis and treatment capabilities for psoriasis across medical institutions at all levels in the province, reduce variability in care, and ensure medical quality and safety. Additionally, this initiative will promote the optimal use of medical resources, lower the financial burden on patients, and support future research through big data collection and analysis, ultimately achieving patient-centered, precise, and personalized treatment. This effort also represents Sichuan Province’s concrete implementation of the national healthcare quality improvement initiative, demonstrating innovative exploration in chronic disease management by the health system. It will accumulate valuable experience for quality control efforts in other chronic diseases and serve as a model for elevating the overall level of dermatological prevention and treatment across the province.